You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Express Scripts
Moodys
AstraZeneca
Colorcon

Last Updated: June 1, 2020

DrugPatentWatch Database Preview

Xellia Pharms Aps Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?

XELLIA PHARMS APS has fourteen approved drugs.

There are two US patents protecting XELLIA PHARMS APS drugs.

There are twenty patent family members on XELLIA PHARMS APS drugs in twenty-two countries and twenty-five supplementary protection certificates in nine countries.

Summary for Xellia Pharms Aps
International Patents:20
US Patents:2
Tradenames:9
Ingredients:9
NDAs:14

Drugs and US Patents for Xellia Pharms Aps

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-001 Feb 15, 2019 RX Yes Yes 10,188,697   Start Trial Y   Start Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride INJECTABLE;INJECTION 204125-001 Dec 28, 2015 AP RX No No   Start Trial   Start Trial
Xellia Pharms Aps POLYMYXIN B SULFATE polymyxin b sulfate INJECTABLE;INJECTION 202766-001 Jan 15, 2014 AP RX No No   Start Trial   Start Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-001 Feb 15, 2019 RX Yes Yes 10,039,804   Start Trial Y   Start Trial
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-003 Feb 15, 2019 RX Yes Yes 10,039,804   Start Trial Y   Start Trial
Xellia Pharms Aps BACITRACIN bacitracin INJECTABLE;INJECTION 203177-001 Aug 25, 2014 AP RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Xellia Pharms Aps Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1280520 C01280520/01 Switzerland   Start Trial PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 60565 01.02.2012
0440372 SPC/GB02/031 United Kingdom   Start Trial PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
0620232 C300076 Netherlands   Start Trial PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0536515 2006/030 Ireland   Start Trial PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
1273292 C01273292/01 Switzerland   Start Trial PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
1115417 06C0022 France   Start Trial PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
Baxter
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.